Tremfya® (Guselkumab) Studies Underscore Its Potential to Be the Only Il-23 Inhibitor to Offer Both Subcutaneous and Intravenous Induction
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.